Q1 2025 Earnings Conference Call May 16, 2025 10:00 AM ET. Company Participants. Andrew Barwicki - IR Representative Hermann Luebbert - CEO, Chairma ...

Unresolved Treatment Needs in IPF. Idiopathic Pulmonary Fibrosis (IPF) is a progressive, irreversible, and fatal interstitial lung disease characterized ...

If you’ve been on TikTok or any other social media — or any kind of media, for that matter — you’ve probably come across ...

Sarepta Therapeutics, Inc. , the leader in precision genetic medicine for rare diseases, today reported new results from Study 9001-103. Also known as ENDEAVOR, Study 9001-103 is a multi-cohort study ...

Good afternoon, ladies and gentlemen, and welcome to the at NRx Pharmaceuticals first-quarter 2025 earnings call. (Operator Instructions) This call is being recorded on Thursday, May 15, 2025. I would ...

Omeros Corp Earnings Call ...

LYTENAVA (bevacizumab gamma) on track for planned first commercial launches in Germany and the United Kingdom (UK) in Q2 CY2025Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025 in th ...

In today’s fast-paced world, maintaining a balanced lifestyle can be a daunting challenge, especially when trying to optimize health and well-being. ProZenith emerges as a powerful ally in this quest, ...

Explore the Benefits of Red, Green, and White Vein Kratom Strains – Discover the Best Kratom Extracts for Energy, Relaxation, ...

Travere Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for traditional approval of FILSPARI (sparsentan) ...

Quince Therapeutics advances Ataxia-Telangiectasia treatment with innovative AIDE platform, insider support, and NEAT Phase 3 ...

Chemomab Therapeutics Ltd.(Nasdaq:CMMB), (Chemomab), a clinical-stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced ...